Identifying medicinal products suitable for an INN Prescription

Robert Vander Stichele, MD, PhD, Ghent University
Research in Advanced Medical Informatics and Technology (RAMIT)
Department of Clinical Pharmacology
Open Medicines Expert Council, Brussels, Wednesday, November 09, 2016
When issuing a prescription a prescribing physician expresses a therapeutical intent

Either
by prescribing a specific medicinal product available on the market of his country
  Branded original
  Branded generic

Either
by issuing an INN prescription indicating a group of (fairly) similar medicinal products, expected to all fullfil the therapeutical intent, from a clinical point of view, with a delegation of specific choice to pharmacist and/or patient
When the pharmacist responds to a prescription by dispensing a medicinal product

He/she can

Either
Comply perfectly to a specific prescription for a branded originator or generic

Either
Substitute the prescribed specific medicinal product with another a specific medicinal product (originator or generic)

Either
Respond to an INN prescription by choosing in the group of (fairly) similar medicinal products, the most appropriate one
E-Prescribing

a) OR: Prescribing of branded products
   (Originators or branded generics)

PhPID Sub Stre Form Route MPID PCID

B) OR: INN – prescribing

Substance (abstraction) Strength Form / Route Ontology + POSOLOGY AND DURATION
E-dispensing

PhPID | Sub | Stre | Form | Route | MPID | PCID GTIN | BaID

+ dispensing advice
INN-Group sharing the same basic attributes

<table>
<thead>
<tr>
<th>PhPID</th>
<th>Sub</th>
<th>Stre</th>
<th>Form</th>
<th>Route</th>
<th>MPID</th>
<th>PCID</th>
</tr>
</thead>
<tbody>
<tr>
<td>PhPID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PhPID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PhPID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PhPID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PhPID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PhPID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PhPID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PhPID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PhPID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PhPID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PhPID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PhPID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PhPID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PhPID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PhPID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PhPID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PhPID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PhPID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PhPID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PhPID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PhPID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PhPID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PhPID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Dm+d
SAM Belgium
INN prescribing

Virtual Therapeutic Moiety

Creating a link

Virtual

Actual

MPID
PCID

Marketing Authorisation Holder

Country

MPID
PCID

PhPID

Strength Form Route

Substance

Creating a link

Virtual

Actual
Federated Drug information databases, linking national drug product databases and international drug knowledge databases

Vidal

BNF

UK : Dm+d

National Agencies databases

SFINX : interaction database

E-health authentic database of medicines

Knowledge databases
Use cases

Identifying correctly VTM groups for INN prescribing

Simplifying Cross border prescribing

Harmonisation of national substitution rules

Facilitating international decision support systems

Creating a federated European Drug Database
Requirements

• A European database of VMP-groups
  • Estimated number of records to be maintained (between 3,000 and 9,000)
• Standards for substance (at two levels), codification of the EURD-list in the PSUR project, an ontology for substances
• Standardized Measures of strength, administration units, pharmaceutical form, route of administration
• An ontology for form/routes